Tiziana Life Sciences announced the Investigational New Drug, IND, application filing for milciclib in combination with gemcitabine for non-small cell lung cancer, NSCLC. "This Phase 2 IND filing, which was achieved with minimal additional resource deployment, enhances the asset value and Tiziana’s optionality for milciclib," commented Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana. "Milciclib previously showed encouraging results in several cancer clinical studies – both as a monotherapy and in combination with gemcitabine. We believe that there could be an important role for a pan-CDK inhibitor in the oncologist’s toolbox. At the same time, we are highly focused on advancing our leading CNS-focused programs with intranasal foralumab, which continues to generate encouraging data in our expanded access trial of secondary progressive multiple sclerosis."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TLSA:
- Tiziana announces clinical improvements in second patient with non-active SPMS
- Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) – Updated Interim Results for the Six Months Ended 30 June 2022
- Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) – Interim Results for the Six Months Ended 30 June 2022
- Tiziana to Participate in January Investor Meetings
- Tiziana Life Sciences completes prerequisite pre-clinical safety study
